Direct class I HLA antigen discovery to distinguish virus-infected and cancerous cells

References

• Terhorst C, Parham P, Mann DL, Strominger JL. Structure of HLA antigens: amino acid and carbohydrate compositions and NH2-terminal sequences of four antigen preparations. Proc. Natl Acad. Sci. USA73(3), 910–914 (1976).
   PubMed Web of Science ®Google Scholar
• Rock KL, Gramm C, Rothstein L et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell78(5), 761–771 (1994).
   PubMed Web of Science ®Google Scholar
• Garcia K, Degano M, Pease LR et al. Structural basis of plasticity in T-cell receptor recognition of a self peptide-MHC antigen. Science279(5354), 1166–1172 (1998).
   PubMed Web of Science ®Google Scholar
• Robinson J, Marshall M, Parham P et al. IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex. Nucleic Acids Res.31(1), 311–314 (2003).
   PubMed Web of Science ®Google Scholar
• Krahenbuhl O, Rey C, Jenne D et al. Characterization of granzymes A and B isolated from granules of cloned human cytotoxic T lymphocytes. J. Immunol.141(10), 3471–3477 (1988).
   PubMed Web of Science ®Google Scholar
• Sandberg J, Fast N, Nixon D. Functional heterogeneity or cytokines and cytolytic effector molecules in human CD8+ T lymphocytes. J. Immunol.167(1), 181–187 (2001).
   PubMed Web of Science ®Google Scholar
• Parham P, Ohta T. Population biology of antigen presentation by MHC class I molecules. Science272(5276), 723–725 (1996).
   Google Scholar
• Stevanovic S. Antigen processing is predictable: from genes to T cell epitopes. Transpl. Immunol.14(3–4), 171–174 (2005).
   PubMed Web of Science ®Google Scholar
• Parker KC, Bednarek M, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding individual peptide side-chains. J. Immunol.152(1), 163–175 (1994).
   PubMed Web of Science ®Google Scholar
• Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics50(3–4), 213–219 (1999).
   PubMed Web of Science ®Google Scholar
• Gulukota K, Sidney J, Sette A, DeLisi C. Two complementary methods for predicting peptides binding major histomcompatibility complex molecules. J. Mol. Biol.267(5), 1258–1267 (1997).
   PubMed Web of Science ®Google Scholar
• Peters B, Tong W, Sidney J, Sette A, Weng Z. Examining the independent binding assumption for binding of peptide epitopes to MHC-1 molecules. Bioinformatics19(14), 1765–1772 (2003).
   PubMed Web of Science ®Google Scholar
• Altuvia Y, Margalit H. A structure-based approach for prediction of MHC-binding peptides. Methods34(4), 454–459 (2004).
   Google Scholar
• Segal MR, Cummings M, Hubbard AE. Relating amino acid sequence to phenotype: analysis of peptide-binding data. Bioinformatics57(2), 632–642 (2001).
   Google Scholar
• Lim JS, Kim S, Lee HG, Lee KY, Kwon TJ, Kim K. Selection of peptides that bind to the HLA-A2.1 molecule by molecular modeling. Mol. Immunol.33(2), 221–230 (1996).
   PubMed Web of Science ®Google Scholar
• Kesmir C, Nussbaum A, Schild H, Detours V, Brunak S. Prediction of proteasome cleavage motifs by neural networks. Protein Eng.15(4), 287–296 (2002).
   PubMedGoogle Scholar
• Reche PA, Glutting J, Reinherz EL. Prediction of MHC class I binding peptides using profile motifs. Hum. Immunol.63(9), 701–709 (2002).
   PubMed Web of Science ®Google Scholar
• Hakenberg J, Nussbaum A, Schild H et al. MAPPP: MHC class I antigenic peptide processing prediction. Appl. Bioinformatics2(3), 155–158 (2003).
   Google Scholar
• Tenzer S, Peters B, Bulik S et al. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol. Life Sci.62(9), 1025–1037 (2005).
   PubMed Web of Science ®Google Scholar
• Kessler JH, Mommaas B, Mutis T et al. Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides. Hum. Immunol.64(2), 245–255 (2003).
   PubMed Web of Science ®Google Scholar
• van der Burg SH, Visseren M, Brandt RM, Kast WM, Melief CJ. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol.156(9), 3308–3314 (1996).
   PubMed Web of Science ®Google Scholar
• Ottenhoff TH, Geluk A, Toebes M, Benckhuijsen WE, van Meijgaarden KE, Drijfhout JW. A sensitive fluorometric assay for quantitatively measuring specific peptide binding to HLA class I and class II molecules. J. Immunol. Methods200(1–2), 88–97 (1997).
   Google Scholar
• Parker KC, Carreno B, Sestak L, Utz U, Biddison WE, Coligan JE. Peptide binding to HLA-A2 and HLA-B27 isolated from Escherichia coli. J. Biol. Chem.267(8), 5451–5459 (1992).
   PubMed Web of Science ®Google Scholar
• Feltkamp MC, Vierboom M, Kast WM, Melief CJ. Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity. Mol. Immunol.31(18), 1391–1401 (1994).
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Riley J, Igarashi T, Li Y, Robbins PF, Rosenberg SA. Immunization of patients with the hTERT: 540–548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin. Cancer Res.10(14), 4688–4698 (2004).
   PubMed Web of Science ®Google Scholar
• Dutoit V, Taub R, Papadapoulos KP et al. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J. Clin. Invest.110(12), 1813–1822 (2002).
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Eliyahu S, Sakaguchi K et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med.180(1), 347–352 (1994).
   PubMed Web of Science ®Google Scholar
• Tsai V, Southwood S, Sidney J et al. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol.158(4), 1796–1802 (1997).
   Google Scholar
• Yang OO, Kalams S, Rosenzweig M et al. Efficient lysis of human immunodeficiency virus type-1 infected cells by cytotoxic T lymphocytes. J. Virol.70(9), 5799–5806 (1996).
   PubMed Web of Science ®Google Scholar
• Viatte S, Alves P, Romero P. Reverse immunology approach for the identification of CD8 T-cell-defined antigens: Advantages and hurdles. Immunol. Cell Biol.84(3), 318–330 (2006).
   PubMed Web of Science ®Google Scholar
• Townsend A, Bastin J, Gould K et al. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J. Exp. Med.168(4), 1211–1224 (1988).
   PubMed Web of Science ®Google Scholar
• Minev B, Hipp J, Firat H, Schmidt J, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc. Natl Acad. Sci. USA97(9), 4796–4801 (2000).
   PubMed Web of Science ®Google Scholar
• Vonderheide R, Hahn W, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity10(6) 673–679, (1999).
   PubMed Web of Science ®Google Scholar
• Ayyoub M, Migliaccio M, Guillaume P et al. Lack of tumor recognition by hTERT peptide 540–548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. Eur. J.Immunol.31(9), 2642–2651 (2001).
   Google Scholar
• Lemmel C, Stevanovic S. The use of HPLC-MS in T-cell epitope identification. Methods29(3), 248–259 (2003).
   PubMed Web of Science ®Google Scholar
• Wallny HJ, Deres K, Faath S et al. Identification and quantification of a naturally presented peptide as recognized by cytotoxic T lymphocytes specific for an immunogenic tumor variant. Int. Immunol.4(10), 1085–1090 (1992).
   PubMed Web of Science ®Google Scholar
• Christinck ER, Luscher M, Barber BH, Williams DB. Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature352(6330), 67–70 (1991).
   PubMed Web of Science ®Google Scholar
• Hunt DF, Henderson R, Shabanowitz J et al. Characterization of peptides bound to the class I molecule HLA-A2.1 by mass spectrometry. Science255(5049), 1261–1363 (1992).
   PubMed Web of Science ®Google Scholar
• Turnquist HR, Schenk E, McIlhaney MM, Hickman HD, Hildebrand WH, Solheim JC. Disparate binding of chaperone proteins by HLA-A subtypes. Immunogenetics53(10–11), 830–834 (2002).
   PubMed Web of Science ®Google Scholar
• Barnea E, Beer I, Patoka R et al. Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor-specific antigens. Eur. J. Immunol.32(1), 213–222 (2002).
   PubMed Web of Science ®Google Scholar
• Bettinotti MP, Hadzikadic L, Ruppe E, Dhillon G, Stroncek DS, Marincola FM. New HLA-A, -B, and -C locus-specific primers for PCR amplification from cDNA: application in clinical immunology. J. Immunol. Methods279(1–2), 143–148 (2003).
   PubMed Web of Science ®Google Scholar
• Prilliman K, Lindsey M, Zuo Y, Jackson KW, Zhang Y, Hildebrand W. Large-scale production of class I bound peptides: assigning a signature to HLA‘-hB*1501. Immunogenetics45(6), 379–385 (1997).
   PubMed Web of Science ®Google Scholar
• Hickman HD, Batson C, Prilliman KR, Crawford DL, Jackson KL, Hildebrand WH. C-terminal epitope tagging facilitates comparative ligand mapping from MHC class I positive cells. Hum. Immunol.61(12), 1339–1346 (2000).
   PubMed Web of Science ®Google Scholar
• Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature351(6324), 290–296 (1991).
   PubMed Web of Science ®Google Scholar
• Toes RE, Nussbaum AK, Degermann S et al. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J. Exp. Med.194(1), 1–12 (2001).
   PubMed Web of Science ®Google Scholar
• Buchli R, VanGundy R, Giberson CF, Hildebrand WH. Critical factors in the development of fluorescence polarization-based peptide binding assays: an equilibrium study monitoring specific peptide binding to soluble HLA-A*0201. J. Immunol. Methods314(1–2) 38–53, (2006).
   PubMed Web of Science ®Google Scholar
• Anderson MLM, Ruhwald M, Nissen MH, Buus S, Claesson MH. Self-peptides with intermediate capacity to bind and stabilize MHC class I molecules may be immunogenic. Scand. J. Immunol.57(1), 21–27 (2003).
   PubMed Web of Science ®Google Scholar
• Sette A, Vitiello A, Reherman B et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol.153(12), 5586–5592 (1994).
   PubMed Web of Science ®Google Scholar
• Keogh E, Fikes J, Southwood S, Celis E, Chesnut R, Sette A. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J. Immunol.167(2), 787–796 (2001).
   PubMed Web of Science ®Google Scholar
• Skipper JC, Gulden P, Hendrickson RC et al. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int. J. Cancer82(5), 669–677 (1999).
   PubMed Web of Science ®Google Scholar
• Hofmann S, Glückmann M, Kausche S et al. Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by Nano-LC MALDI MS/MS. Mol. Cell Proteomics4(12), 1888–1897 (2005).
   PubMed Web of Science ®Google Scholar
• Krämer BF, Schoor O, Kruger T et al. MAGED4-Expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue. Cancer Biol. Ther.4(9), 943–948 (2005).
   PubMed Web of Science ®Google Scholar
• van Els CA, Herberts C, van der Heeft E et al. A single naturally processed measles virus peptide fully dominates the HLA-A*0201-associated peptide display and is mutated at its anchor position in persistent viral strains. Eur. J. Immunol.30(4), 1172–1181 (2000).
   PubMed Web of Science ®Google Scholar
• Rotzschke O, Falk K, Deres K et al. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature348(6298) 252–254 (1990).
   PubMed Web of Science ®Google Scholar
• Herberts CA, Meiring H, van Gaans-van den Brink JA et al. Dynamics of measles virus protein expression are reflected in the MHC class I epitope display. Eur. J. Immunol.39(10), 567–575 (2003).
   Google Scholar
• di Marzo Veronese F, Arnott D, Barnaba V et al. Autoreactive cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected subjects. J. Exp. Med.183(6), 2509–2516 (1996).
   PubMed Web of Science ®Google Scholar
• Herberts CA, van Gaans-van den Brink JA, van der Heeft E et al. Autoreactivity against induced or upregulated abundant self-peptides in HLA-A*0201 following measles virus infection. Hum. Immunol.64(1), 44–55 (2003).
   PubMed Web of Science ®Google Scholar
• Hickman HD, Luis A, Bardet W et al. Cutting edge: class I presentation of host peptides following HIV infection. J. Immunol.171(1), 22–26 (2003).
   PubMed Web of Science ®Google Scholar
• Loriot A, de Plaen E, Boon T, de Smet C. Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells. J. Biol. Chem.281(15) 10118–10126 (2006).
   PubMed Web of Science ®Google Scholar
• Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. Localization, quantitation, and in situ detection of specific peptide–MHC class I complexes using a monoclonal antibody. Immunity6(6), 715–726 (1997).
   PubMed Web of Science ®Google Scholar
• Wittman V, Woodburn D, Nguyen T, Neethling FA, Wright S, Weidanz JA. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death. J. Immunol.177(6) 4187–4195 (2006).
   PubMed Web of Science ®Google Scholar
• Sercarz EE, Lehmann P, Ametani A, Benichou G, Miller A, Moudgil K. Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol.11, 729–766 (1993).
   PubMed Web of Science ®Google Scholar
• Celis E. Getting peptide vaccines to work: just a matter of quality control? J. Clin. Invest.110(12), 1765–1768 (2002).
   PubMed Web of Science ®Google Scholar
• Crowe SR, Turner S, Miller SC et al. Differential antigen presentation regulates the changing patterns of CD8+T cell immunodominance in primary and secondary influenza virus infections. J. Exp. Med.198(3) 339–410 (2003).
   Google Scholar